Anti-Aging Investigational

SS-31

A mitochondria-targeted peptide studied for cellular energy and tissue-protection questions.

MitochondriaCellular EnergyInvestigational

Also referenced as: Elamipretide

Also appears in: Recovery

Price compare
79 tracked offers across 79 vendors · 19 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $1.13/mg
From
$1.13/mg
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Anti-Aging

Primary lane: Anti-Aging. Also surfaces under Recovery for browsing and discovery.

Aliases
1

Elamipretide

Signal depth
Medium

FDA label signal · 32 trials · 452 PubMed results

Promising
Research evidence

SS-31 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

SS-31 has 32 name-matched clinical trials (3 international) (highest phase: Phase 4) and 452 PubMed-indexed publications and is not FDA-approved. 14 trials have posted results. Note: 1 retracted publication in the literature.

🌍 3 international trials ⚠ 1 retracted publication
Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE3 · Randomized ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) PHASE3 · Randomized A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension PHASE3 · Randomized Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) ISRCTN · Phase 4 A Phase IIIb/IV, randomized, double-blind, parallel-group, placebo-controlled, trial to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in patients with genetically confirmed Barth syndrome ISRCTN · Phase 3 ReNEW: a clinical trial investigating the efficacy and safety of elamipretide in subjects who have dry age-related macular degeneration (Dry AMD) Journal of the American Society of Nephrology · 483 citations The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What SS-31 is

SS-31 is a mitochondria-targeted peptide commonly referenced in energy, recovery, and aging-related research discussions. In development contexts it is often referred to as elamipretide.

Why it matters

It sits in the same broad mitochondrial-interest lane as MOTS-c and humanin, but with a more explicit investigational-development framing.

Regulatory context

SS-31 is not FDA approved in the United States. It is better classified here as investigational rather than as an approved therapy.

Practical reading note

Mitochondrial peptides often sound especially advanced in marketing copy, so it helps to distinguish mechanistic intrigue from actual clinical availability.